Carisma Therapeutics, Inc. (NASDAQ:CARM) Given Average Rating of “Hold” by Analysts

Shares of Carisma Therapeutics, Inc. (NASDAQ:CARM) have earned an average recommendation of “Hold” from the seven ratings firms that are currently covering the firm, Marketbeat reports. Five analysts have rated the stock with a hold rating, one has assigned a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $4.94.

A number of equities research analysts have recently issued reports on the company. Evercore ISI reiterated an “in-line” rating and issued a $0.70 target price (down previously from $4.00) on shares of Carisma Therapeutics in a research note on Wednesday, December 11th. BTIG Research downgraded shares of Carisma Therapeutics from a “buy” rating to a “neutral” rating in a research report on Tuesday, December 10th. D. Boral Capital reduced their target price on shares of Carisma Therapeutics from $24.00 to $12.00 and set a “buy” rating on the stock in a research report on Monday, December 9th. EF Hutton Acquisition Co. I upgraded shares of Carisma Therapeutics to a “strong-buy” rating in a research note on Wednesday, October 30th. Finally, Baird R W downgraded shares of Carisma Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, December 12th.

Carisma Therapeutics Trading Up 6.3 %

Shares of CARM stock opened at $0.43 on Thursday. Carisma Therapeutics has a fifty-two week low of $0.40 and a fifty-two week high of $3.16. The firm’s 50 day moving average price is $0.89 and its two-hundred day moving average price is $1.03. The stock has a market cap of $17.96 million, a price-to-earnings ratio of -0.28 and a beta of 1.44. The company has a quick ratio of 3.23, a current ratio of 3.23 and a debt-to-equity ratio of 1.39.

Carisma Therapeutics (NASDAQ:CARM) last posted its earnings results on Thursday, November 7th. The company reported ($0.31) earnings per share for the quarter, meeting the consensus estimate of ($0.31). Carisma Therapeutics had a negative net margin of 314.78% and a negative return on equity of 957.20%. The business had revenue of $3.39 million for the quarter. On average, analysts anticipate that Carisma Therapeutics will post -1.32 EPS for the current year.

Hedge Funds Weigh In On Carisma Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in CARM. Point72 Asia Singapore Pte. Ltd. bought a new stake in Carisma Therapeutics during the second quarter valued at $40,000. Vanguard Group Inc. lifted its holdings in Carisma Therapeutics by 0.7% in the 1st quarter. Vanguard Group Inc. now owns 1,579,961 shares of the company’s stock valued at $3,587,000 after acquiring an additional 11,200 shares during the last quarter. Wexford Capital LP boosted its holdings in Carisma Therapeutics by 75.5% during the third quarter. Wexford Capital LP now owns 34,861 shares of the company’s stock worth $34,000 after buying an additional 15,000 shares in the last quarter. Finally, Barclays PLC grew its position in Carisma Therapeutics by 3,661,933.3% in the third quarter. Barclays PLC now owns 549,305 shares of the company’s stock worth $539,000 after buying an additional 549,290 shares during the last quarter. 44.27% of the stock is currently owned by hedge funds and other institutional investors.

Carisma Therapeutics Company Profile

Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.